

Total Synthesis of (+)-Cochlearol B by an Approach Based on a Catellani Reaction and Visible-Light-Enabled [2+2] Cycloaddition

Alistair D. Richardson, Trenton R. Vogel, Emily F. Traficante, Kason J. Glover, and Corinna S. Schindler*


A. Selected Meroterpenoids Isolated from *Ganoderma cochlear*





cochlearol A (1) from *Ganoderma* cochlear renoprotective effects

cochlearol B (2) from Ganoderma cochlear renoprotective effects (-)-cochlearol B (2) only




ganocin B (3) from *Ganoderma* cochlear structurally related to AChE inhibitors


Ganoderma meroterpenoids including cochlearol B (2).

DOI: 10.1002/anie.202201213

B. Retrosynthetic Strategy Towards Cochlearol B (2)



Retrosynthetic strategy towards cochlearol B (2) relying on Catellani and [2+2] cycloaddition reactions. Proceeds through an EDBAC ring formation sequence.



$\begin{array}{c} \textbf{BAKER-VENKATARAMAN REARRANGEMENT}\\ (References are on page 542) \\ \hline \\ \textbf{P} & \textbf{P} &$

R¹ = alkyl, aryl, NH₂; R² = alkyl, aryl; <u>base:</u> KOH, KOt-Bu, NaH, Na metal, KH, C₅H₅N

Mechanism: 18-22

In the first step of the mechanism, the aromatic ketone is deprotonated at the α -carbon and an enolate is formed. This nucleophile attacks the carbonyl group of the acyloxy moiety intramolecularly to form a tetrahedral intermediate that subsequently breaks down to form the aromatic β -diketone.






 Table S1. (A) Evaluation of asymmetric conjugate addition conditions. (B) Control reaction without copper.


A. Conditions evaluated for an asymmetric copper-catalyzed conjugate addition



B. Background reactivity likely responsible for racemic product observed




Entry	Catalyst	Ligand	ee (%)	
1	CuBr (SMe ₂)	L1	0	
2	Cul	L1	0	
3	CuBr (SMe ₂)	L2	0	
4	CuBr·(SMe ₂)	L3	0	
5	Cul	L4	0	
6	CuBr (SMe ₂)	L5	0	
7 ^a	CuBr (SMe ₂)	L1	0	
8 ^a	Cul	L1	0	
9 ^a	CuBr (SMe ₂)	L2	0	
10 ^a	Cul	L2	0	
11 ^a	CuBr·(SMe ₂)	L3	0	
12 ^a	Cul	L3	0	
13 ^a	CuBr·(SMe ₂)	L4	0	
14 ^a	Cul	L4	0	




^a Reaction performed without TMSCI


A. First Generation Catellani Approach: Challengens due to Competing [4+2] Cycloaddition




B. [2+2] Cycloaddition: Challenges due to Competing Cyclopropanation



Catellani Reaction





J. Am. Chem. Soc., 2004, 126, 78.



Nature, 2017, 551, 489.

C. Mechanistic Hypothesis for the Formation of 19:





Kabbe Condensation







Table S2. Evaluation of asymmetric Kabbe condensation conditions.







Entry	Catalyst	Additive	Yield (%)	ee (%)
1	(R)-2-methylpyrrolidine (C1)	butyric acid	5	23
2	(S)-2-diphenylmethylpyrrolidine (C2)	butyric acid	NR	-
3	(S)-2-(methoxymethyl)pyrrolidine (C3)	butyric acid	NR	-
4	(R)-5-(hydroxylmethyl)-2-pyrrolidine (C4)	butyric acid	NR	-
5	(S)-5-(2-pyrrolidinyl)-1H-tetrazole (C5)	butyric acid	NR	-
6	(S)-1-boc-2-pyrrolidinecarbonitrile (C6)	butyric acid	NR	-
7	L-prolinamide (C7)	butyric acid	7	7
8	(3S,8aS)-3-methyloctahydropyrrolo[1,2-a]pyrazine] (C8)	butyric acid	NR	-
9	(2S,5R)-2,5-dimethylpyrrolidine (C9)	butyric acid	NR	-
10	(S)-5-benzyl-2,2,3-trimethylimidazolidin-4-one monohydrochloride (C10)	-	NR	-
11	(S)-5-benzyl-2,2,3-trimethylimidazolidin-4-one dichloroacetic acid (C11)	-	NR	-
12	(S)-2-(tertbutyl)-3-methylimidazolidin-4-one trifluoroacetic acid (C12)	-	NR	-

13	(2S,5S)-5-benzyl-2-(tertbutyl)-3-methylimidazolidin-4-one (C13)	butyric acid	NR	-	
14 ^a	(R)-2-methylpyrrolidine (C1)	butyric acid	19	0	
15 ^b	(S)-2-(methoxymethyl)pyrrolidine (C3)	butyric acid	26	12	
16 ^b	(R)-2-methylpyrrolidine (C1)	butyric acid	30	9	
17 ^b	(S)-2-diphenylmethylpyrrolidine (C2)	butyric acid	3	16	

^a Reaction performed at 50 °C. ^b 3 eq. of the catalyst and 1 eq. of the additive were used. NR = no reaction.

